Source comparison
Research Peptides for Stroke Recovery: Compound Comparison
BPC-157 VEGF upregulation and eNOS stabilization; promotes angiogenesis and axonal regrowth 0–72 hours post-stroke; sustained for 14–28 days Subcutaneous injection at 200–500 mcg daily Reduced MCAO infarct volume by 34% in rodent models; human trials pending B
This comparison does not assign a generated winner or score.
- BPC-157
- VEGF upregulation and eNOS stabilization; promotes angiogenesis and axonal regrowth
- 0–72 hours post-stroke; sustained for 14–28 days
- Subcutaneous injection at 200–500 mcg daily
- Reduced MCAO infarct volume by 34% in rodent models; human trials pending
- Best for vascular repair and long-term structural recovery; limited acute neuroprotection
- Cerebrolysin
- Delivers exogenous NGF, BDNF, and CNTF mimetics; activates TrkA/TrkB signaling
- 12–48 hours post-stroke; administered for 10–21 days
- Intravenous infusion at 30–50 mL daily
- Meta-analysis: 2.8-point NIHSS improvement vs placebo (n=1,501); 21-day protocols outperform 10-day
- Most robust human trial data; requires clinical setting for IV administration
- Semax
- Increases hippocampal BDNF transcription; blocks glutamate excitotoxicity
- 0–6 hours post-stroke; effective through subacute phase
- Intranasal at 12–18 mg daily or subcutaneous at 300–600 mcg
- 40% infarct volume reduction in MCAO models; improved cognitive scores in Phase II trial
- Fastest CNS penetration; ideal for acute neuroprotection; less evidence for chronic recovery